ADCT-601 Targeting AXL

ADCT-601 is an ADC composed of a humanized monoclonal antibody that binds to human AXL (licensed from BerGenBio), conjugated using Glycoconnectâ„¢ technology (licensed from Synaffix BV) to a linker with a PBD-dimer toxin. Once bound to an AXL-expressing cell, ADCT-601 is internalized into the cell, where enzymes release the PBD-based warhead. AXL is an ideal target for an ADC approach, as it is highly overexpressed in many solid tumors (eg, lung, breast, prostate, pancreas, glioma, and esophageal) and hematological malignancies (eg, acute and chronic myeloid leukemia).

ADCT-601 is being evaluated in a phase 1 clinical trial in patients with selected advanced solid tumors (NCT03700294).